EP1482946A1 - Systeme d'administration de medicament oral a base de progesterone - Google Patents

Systeme d'administration de medicament oral a base de progesterone

Info

Publication number
EP1482946A1
EP1482946A1 EP02707980A EP02707980A EP1482946A1 EP 1482946 A1 EP1482946 A1 EP 1482946A1 EP 02707980 A EP02707980 A EP 02707980A EP 02707980 A EP02707980 A EP 02707980A EP 1482946 A1 EP1482946 A1 EP 1482946A1
Authority
EP
European Patent Office
Prior art keywords
progesterone
polyethylene glycol
dosage form
solid
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02707980A
Other languages
German (de)
English (en)
Inventor
Domingo Y. Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Finance LLC
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of EP1482946A1 publication Critical patent/EP1482946A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Definitions

  • This invention relates to oral dosage forms of hormones and methods for their delivery to subjects needing hormone therapy.
  • an oral dosage form suitable to deliver a combined dosage of progesterone and which upon delivery through the gastrointestinal tract provides a blood concentration of from about 0.1 ng/ml to about 400 ng/ml progesterone; said dosage form comprising a combination that includes (a) a first solid form comprising from about 25 mg to about 500 mg micronized progesterone in a solid polyethylene glycol carrier having an average molecular weight of from about 1000 to 10,000 and constituting at least about 30 % of said first solid form; and (b) a second solid form comprising an estrogen.
  • the polyethylene glycol carrier comprises from about 45 % to about 65 % weight of the first solid form.
  • the second solid form (b) contains from about 0.25 mg to about 5 mg of estradiol.
  • the solid polyethylene glycol carrier comprises a mixture of polyethylene glycol 1450, polyethylene glycol 3350 or polyethylene glycol 8000.
  • an oral dosage form suitable to deliver a combined dosage of progesterone and an estrogen via the gastrointestinal tract which upon oral administration provides a blood concentration of from about 0.1 ng/ml to about 400 ng/ml progesterone; said dosage form comprising a combination that includes (a) a first solid form containing from about 25 mg to about 500 mg micronized progesterone, said caplet having been derived from the extrusion of a polymer matrix extruded from a mixture comprising micronized progesterone in a solid polyethylene glycol carrier which is a mixture of polyethylene glycol 1450, polyethylene glycol 3350 or polyethylene glycol 8000, the micronized progesterone having first been dispersed in molten polyethylene glycol, and, after cooling to a solid form, having extruded, said mixture constituting from about 45 % to about 65 % weight of said first solid form; and (b) a second solid form which contains from about 0.25 mg to about 5 mg of estradio
  • the oral dosage form is proivded with said first solid form as a caplet and said second solid form as a tablet.
  • a method of providing an oral dosage of a combination therapy of progesterone and estradiol which comprises administering to a patient an oral dosage form suitable to deliver a combined dosage of progesterone and an estrogen via the gastrointestinal tract which upon oral administration provides a blood concentration of from about 0.1 ng/ml to about 400 ng/ml progesterone; said dosage form comprising a combination that includes (a) a first solid form containing from about 25 mg to about 500 mg micronized progesterone, said caplet having been derived from the extrusion of a polymer matrix extruded from a mixture comprising micronized progesterone in a solid polyethylene glycol carrier which is a mixture of polyethylene glycol 1450, polyethylene glycol 3350 or polyethylene glycol 8000, the micronized progesterone having first been disper
  • the invention features a solid oral dosage form of progesterone comprising a therapeutically effective amount of micronized progesterone and a solid polymeric carrier, wherein the dosage form, upon oral administration, provides a therapeutically effective amount of progesterone to a subject.
  • a preferred solid polymeric carrier is a mixture of polyethylene glycols of molecular weight ranging from about 1,000 to about 10,000.
  • progesterone dosage forms of this invention can be prepared by injection molding techniques. Further, the dosage form can be prepared for immediate release or controlled release.
  • the dosage form can be a tablet, capsule, caplet, encapsulated pellets, encapsulated granules, powder, or encapsulated powder. These dosage forms can be provided as unit dosage forms.
  • the polyethylene glycol is polyethylene glycol 1450, polyethylene glycol 3350 or polyethylene glycol 8000, or a mixture thereof.
  • the cellulose ether is a hydroxyalkyl cellulose, carboxyalkyl cellulose, or a mixture thereof.
  • the cellulose ether is hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, carboxy ethyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate trimellitate, or a mixture thereof.
  • an oral progesterone unit dosage form which comprises micronized progesterone and a solid polymeric carrier, wherein the dosage form, upon oral administration, provides a therapeutically effective amount of progesterone to a subject, wherein, the dosage form comprises from about 25 mg to about 500 mg of micronized progesterone per dose; the solid polymeric carrier constitutes from about 45 % to about 65 % weight of the dosage form and comprises a mixture of polyethylene glycol 1450, polyethylene glycol 3350 or polyethylene glycol 8000.
  • a combination dosage form which comprises an oral progesterone dosage form and an estrogen dosage form, wherein the combination dosage form is a capsule which encloses the progesterone dosage form and the estrogen dosage form; the oral progesterone dosage form is a caplet comprising micronized progesterone and a solid polymeric carrier, which progesterone dosage form, upon oral administration, provides a therapeutically effective amount of progesterone to a subject, and the progesterone dosage form comprises from about 25 mg to about 500 mg of micronized progesterone per dose and the solid polymeric carrier constitutes from about 45 % to about 65 % weight of the progesterone dosage form and comprises a mixture of polyethylene glycol 1450, polyethylene glycol 3350 or polyethylene glycol 8000, and the therapeutically effective amount of progesterone represents a blood concentration of from about 0.1 ng/ml to about 400 ng/ml and the oral estrogen dosage form is an estradiol tablet comprising estradiol from about 0.25 mg to
  • This invention further provides a hormone replacement therapy by administering a dosage form described above to a subject in need of progesterone or a combination of progesterone and estrogen.
  • the method of this invention may be used for treating or preventing various conditions, including, but not limited to, infertility related to non-receptive uterus, premenstrual tension, ovulation, primary dysmenorrhea and endometriosis, habitual abortion, respiratory depression in the Pickwickian syndrome, secondary amenorrhea, dysfunctional uterine bleeding, preeclampsia and toxemia of pregnancy, sexual infantilism, and post-menopausal symptoms.
  • a pharmaceutical may refer to one or more pharmaceuticals for use in the presently disclosed formulations and methods.
  • the term pharmaceutical generally refers to any known pharmacologically active agent as well as its pharmaceutically acceptable salt, prodrug such as an ester or an ether, or a salt of a prodrug, or a solvate such as ethanolate, or other derivative of such pharmacologically active agent.
  • prodrug such as an ester or an ether
  • salt of a prodrug or a solvate such as ethanolate, or other derivative of such pharmacologically active agent.
  • a solvate such as ethanolate
  • this invention contemplates the use of polymorphic, isomeric (including ' stereoisomeric, geometrically isomeric and optically isomeric) and anomeric forms of the pharmaceuticals described herein.
  • pharmaceutical carrier or simply carrier refers to a composition that contains and or delivers a pharmacologically active agent and is generally considered to be otherwise pharmacologically inactive.
  • solid polymeric carrier is meant a carrier that comprises a polymer or a mixture of polymers that is substantially free of oil.
  • a formulation is substantially free of oil when the formulation does not constitute an oil or a mixture of oils primarily to dissolve or disperse a given drug in the formulation. Inclusion of any combination of polymers or oils which would destroy the solid nature of the said first form is excluded from the scope of the invention.
  • Formulation is a pharmaceutical term of art that includes a carrier and a pharmaceutical.
  • Formulation is a broad term and includes the compositions that may or may not have been processed into a dosage form which is ultimately administered to a subject. For example, formulation includes the compositions that are mixed in preparation for manufacturing a dosage form.
  • a dosage form refers to a formulation that is ready for administration to a subject. As used herein, it specifically refers to solid dosage forms, including, but not limited to, tablets, capsules, caplets, powders, pellets, and granules. The term also includes multilayered tablets wherein a given layer may represent a different drug. The term also includes powders, pellets and granules that are encapsulated. The powders, pellets, and granules may be coated with a suitable polymer or a conventional coating material to achieve, for example, greater stability in the gastrointestinal tract, or to achieve the desired rate of release. Moreover, the capsule comprising the powder, pellets or granules may be further coated. The tablet, or the caplet may also be scored to facilitate division of dosing. Alternatively, the dosage forms of the present invention may be unit dosage forms wherein the dosage form is intended to deliver one therapeutic dose per administration.
  • pharmaceutically acceptable means that the ingredient that is being qualified is compatible with other ingredients of the formulation and not injurious to the patient.
  • Several pharmaceutically acceptable ingredients are known in the art and official publications. For example, THE UNITED STATES PHARMACOEPIA describe the analytical criteria for assessing the pharmaceutical acceptability of numerous ingredients of interest. Unless otherwise indicated, the ingredients used in the present invention are pharmaceutically acceptable.
  • Injection molding refers to a process for producing oral solid dosage forms wherein a predetermined amount of the formulation comprising a carrier and a pharmaceutical (along with optional adjuvants) are injected into a mold at a certain temperature and pressure and the mold is cooled and the oral solid dosage form is collected.
  • the mold can be packed with additional amount of the formulation material during the cooling cycle.
  • the dosage form is a tablet or a caplet.
  • a therapeutically effective blood level refers to the blood level of a drug in a subject that is necessary to provide a therapeutic benefit to the subject.
  • the therapeutically effective blood level may vary depending on the therapeutic benefit desired, as well as other variables such as the subject's age, weight, metabolism, physiological conditions such as gastrointestinal motility, renal clearance, etc.
  • the therapeutically effective blood level may be achieved in one or more administrations, applications or dosages. Determination of the dosing needed to achieve a therapeutically effective blood level for a given therapy or treatment is well within the ordinary skill in the pharmaceutical arts.
  • therapeutically effective amount of progesterone is that amount of progesterone effective for one or more of the following, preventing estrogen-induced endometrial hyperplasia in post menopausal women, inducing bleeding in secondary amenorrhea, and reducing endometrial hyperplasia and dysfunctional bleeding in women suffering from such bleeding disorders.
  • the various therapeutically effective blood levels for various treatments are known in the art. See, for example, de Lignieres, B., Oral Micronized Progesterone, Clin. Ther., 21(1): 41-60 (1999), which is incorporated by reference.
  • the therapeutically effective blood levels may range from about 0.1 ng/ml to about 100 ng/ml or more, depending on the condition being treated and the individual patient-related variables such as age, weight, - metabolic activity, etc. See, also for example, the U.S. Patent No. 5,543,150, which is incorporated by reference, which describes some of the therapeutic serum levels.
  • blood level is used interchangeably with terms such as blood concentration, plasma level, plasma concentration, serum level, serum concentration, serum blood level and serum blood concentration.
  • Cmax refers to the maximum serum concentration of progesterone following the oral administration of the solid oral dosage form to patients.
  • Normalized Cmax refers to the value obtained by dividing Cmax into the dosage strength of the solid oral dosage form of progesterone. For example, if the maximum serum concentration of progesterone is 14 ng/ml following the oral administration of a solid oral dosage form containing 200 mg of micronized progesterone, the Cmax is 14 ng/ml and the normalized Cmax is 0.07 ng/ml/mg.
  • AUC refers to the area under the curve that tracks the serum concentration (ng/ml) of progesterone over a given time following the oral administration of the solid oral dosage form to patients.
  • AUC can be measured from 0 to 12 hours or from o to 24 hrs following the administration and in these cases are referred to as AUC(o-i2) or AUC(o- 24 ), respectively.
  • Normalized AUC is obtained by dividing the AUC into the dosage strength of the solid oral dosage form of progesterone. For example, if the AU o- ⁇ ) is 160 hr. ng/ml following the oral administration of a solid oral dosage form containing 200 mg of micronized progesterone, the normalized AUC(o-i2) is 0.8 hr. ng/ml/mg.
  • administration refers to a method of delivering a formulation to a desired site.
  • oral administration refers to ingesting a drug by swallowing or chewing.
  • Subject as used herein refers to a human, both male and female, or an animal (preferably a mammal) that can benefit from the administration of the progesterone formulations of the present invention.
  • a range such as 0.1 to 100 should be considered to have specifically disclosed subranges such as 0.1 to 1, 0.4 to 10, 1-25, 10-50, 25-60, 40-65, 60-80, 70-100, etc, as well as individual numbers within that range, for example, 0.1, 0.4, 1, 5, 7, 11, 15, 19, 22, 28, 35, 39, 44, 60, 65, 78, 84, 89, 95, etc. This applies regardless of the breadth of the range and regardless of the units under consideration.
  • the Dosage Forms This invention provides oral progesterone dosage forms comprising micronized progesterone and a solid polymeric carrier, wherein the dosage forms, upon oral administration, provide a therapeutically effective blood level of progesterone to a subject.
  • the currently available oral progesterone dosage forms comprising micronized progesterone are oil-based and thus do not comprise a solid polymeric carrier.
  • the oral dosage forms of the present invention can be processed into an immediate release or a sustained release dosage form. Immediate release dosage forms may release the progesterone in a fairly short time, for example, within a few minutes to within a few hours. Sustained release dosage forms may release the progesterone over a period of several hours, for example, up to 24 hours or longer, if desired. In either case, the delivery can be controlled to be substantially at a certain predetermined rate over the period of delivery.
  • the oral dosage forms of the present invention can be processed into dosage forms such as tablets, capsules, caplets, powders, encapsulated pellets, encapsulated granules, or encapsulated powders.
  • dosage forms can be coated with a polymeric or other art-known coating materials to achieve, for example, greater stability on the shelf or in the gastrointestinal tract, or to achieve control over drug release.
  • coating techniques and materials used therein are well-known in the art.
  • cellulose acetate phthalate polyvinyl acetate phthalate, hydroxypropylmethyl cellulose phthalate, methacrylic acid-methacrylic acid ester copolymers, cellulose acetate trimellitate, carboxymethylethyl cellulose, and hydroxypropylmethyl cellulose acetate succinate, among others, can be used to achieve enteric coating.
  • Mixtures of waxes, shellac, zein, ethyl cellulose, acrylic resins, cellulose acetate, silicone elastomers can be used to achieve sustained release coating. See, for example, Remington, supra, Chapter 93, for other types of coatings, techniques and equipment.
  • the tablet or caplet dosage form can be scored to facilitate easy break-off to adjust the dosage as needed.
  • the tablets can also be multi-layered, each layer representing a different drug or a different concentration of the same drug.
  • the dosage forms of the present invention can be prepared as unit dosage forms which are intended to deliver one therapeutically effective dose per administration.
  • the present progesterone dosage forms constitute commonly used pharmaceutical excipients to form a stable natural progesterone product without the use of allergenic ingredients such as peanut oil. Further, since the dosage forms of the present invention deliver the natural progesterone, as opposed to synthetic progestins, the undesirable effects of synthetic progestins on liver function and carbohydrate metabolism can be avoided. Additional advantages of these dosage forms include dosing flexibility, convenience, greater patient compliance in a clinical setting and the attendant benefits of improved clinical outcomes.
  • D-form crystals are reported to have a melting point of 121 °C. Merck Index, 12th Edition, pp 1335- 1336, Merck & Co., Inc., White House Stattion, NJ (1996).
  • This invention contemplates using progesterone of either D-form or D-form or a mixture thereof. Accordingly, the term progesterone as used herein refers to either D-form or D-form or a mixture thereof.
  • micronized progesterone refers to a white or creamy white crystalline particulated powder that is practically insoluble in water, wherein virtually all (i.e., greater than 90 %) of the individual progesterone particles in the powder have -been reduced in size to less than about 25 microns in diameter, or in the case of non-round particles, to less than about 25 microns in their largest dimension. In some aspects, virtually all (greater than 90 %) of the micronized progesterone particles have particle sizes of less than 10 microns, and a majority (e.g. 78 %) of these particles have particle sizes of less than 5 microns.
  • Micronized progesterone is available from commercial sources such as Berlichem, a division of Schering AG, and from the Upjohn Company. Alternatively, micronized progesterone can be prepared from bulk progesterone in a radiator mill (jet air micronizer) by techniques well-known in the art. For a description of the micronization techniques and machines, see, for example, U.S. Patent Nos. 2,032,827 and 4,018,388.
  • the dosage form contains from about 50 mg to about 500 mg progesterone per dose. In another preferred embodiment, the dosage form contains from about 10 % to about 70 % (more preferably from about 15 % to about 60 %) by weight of micronized progesterone.
  • the present dosage forms comprise a solid polymeric carrier to deliver micronized progesterone.
  • the solid polymeric carrier may constitute at least 30 % by weight of the first solid form that is made up of the micronized progeseterone and solid polymeric carrier, from about 1 % to about 80 % by weight of the dosage form.
  • the polymeric carrier constitutes from about 20 % to about 70 % by weight of the dosage form.
  • the polymeric carrier constitutes from about 30 % to about 65 % by weight of the first solid form.
  • Polyethylene glycol is available in various grades under several trademarks including Carbowax ® PEG 200, 300, 400, 540 Blend, 900, 1000, 1450, 3350, 4000, 4600, 8000 and compound 20M from Union Carbide Co., USA and Poly Glycols ® E series from Dow chemical Co., USA.
  • the various grades available under a given trademarks represent differences in molecular weight and viscosity.
  • the carrier is a mixture of polyethylene glycols having a molecular weight of from about 100 to about 20,000. In another aspect, the carrier is a mixture of polyethylene glycols having a molecular weight of from about 1000 to about 10,000. In some aspects, the polyethylene glycol is polyethylene glycol 1450, polyethylene glycol 3350 or polyethylene glycol 8000, or a mixture thereof.
  • the carrier may include a mixture of poly vinylpyrrolidones having a mean molecular weight ranging from 2,500 to 3,000,000 or more.
  • the carrier is a cellulose ether.
  • Some exemplary cellulose ethers may include hydroxyalkyl cellulose (such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate trimellitate etc), and carboxyalkyl celluloses (such as carboxymethyl cellulose, carboxyethyl cellulose, etc) or a mixture thereof.
  • the carrier may include adjuvants such as opacifiers, bulking agents, sweeteners, stabilizing agents, etc.
  • opacifiers include titanium dioxide, Talc, calcium carbonate, behenic acid, and cetyl alcohol.
  • bulking agents include starch, microcrystalline cellulose, calcium sulfate, calcium phosphate, and lactose.
  • sweeteners include aspartame, saccharin, sodium cyclamate and Xylitol.
  • stabilizing agents include alginic acid glycerylmonostearate, hydroxypropyl cellulose, magnesium, aluminium silicate, and propylene glycol.
  • the above carriers can be used to prepare dosage forms of this invention that can release the progesterone immediately, i.e., within a few rninutes to within a few hours, or in a sustained manner, i.e. , over a period of 24 hours or longer if desired.
  • the dissolution rate of the progesterone dosage form can be influenced by including adjuvants such as surfactants to the dosage form.
  • Such surfactants may include sodium lauryl sulfate, glyceryl monooleate, sorbitan ester, docusate sodium, and cetrimide.
  • the surfactant may constitute from about 0.1% to about 5 % by weight of the dosage form.
  • a polyethylene glycol dosage form of the present invention as described herein may comprise about 2.5 % by weight sodium lauryl sulfate to provide an immediate release dosage form.
  • additional solid carriers can be used, including, but not limited to, gums, acrylic resins or a mixture thereof.
  • this invention provides a combination dosage form that comprises an oral progesterone dosage form as described above and an oral estrogen dosage form.
  • a combination dosage form can be a tablet, capsule, caplet, powder, encapsulated pellets, encapsulated granules, or encapsulated powder.
  • the combination dosage form can be a capsule which encloses the progesterone dosage form and the estrogen dosage form.
  • the progesterone dosage form and the estrogen dosage form can in turn be independently a tablet, capsule, caplet, powder, encapsulated pellets, encapsulated granules, or encapsulated powder.
  • the progesterone and estrogen can be formulated together into one dosage form such as a powder or a tablet which can be further encapsulated or coated.
  • the combination dosage form is a capsule that encapsulates a progesterone tablet and an estrogen tablet.
  • the combination dosage form is a capsule that encapsulates a progesterone tablet and an estrogen powder.
  • the desired dosage form can be chosen depending on the treatment on hand, as well as the desired order of release of the progesterone and the estrogen.
  • progesterone caplet and an estrogen powder to prepare a combination capsule, one can achieve a quicker release of estrogen (because the estrogen is a powder) and a slower release of progesterone (because the progesterone caplet requires dissolution first). Selection of the proper dosing and the dosage form for a given treatment is well within the ordinary skill in the art.
  • Such combination oral dosage forms are feasible because of the development of the oral progesterone dosage forms of the present invention that comprise a solid polymeric carrier.
  • the solid polymeric carrier unlike the oil-base of the existing dosage forms, allows the production of an oral progesterone dosage form that is of sufficiently small size to facilitate its inclusion, along with an estrogen oral dosage form, in a dosage form such as a capsule to create a dosage form for combination hormone therapy.
  • a combination of estradiol and progesterone can now be obtained in one oral dosage form by placing, for example, one caplet of progesterone and one tablet of estradiol into a capsule such as a size #1 gelatin capsule.
  • the estrogen that can be used for the combination dosage form described above can be any one or more of the estrogens that are known in the art.
  • the estrogen can be natural estrogens or their congeners such as estradiol, estrone, estropipate, ethinyl estradiol, quinestrol, or conjugated estrogens.
  • Synthetic estrogens that may be used include dienestrol, diethylstilbesterol, and mestranol.
  • the estrogen is estradiol.
  • the estrogen dosage can be from about 0.1 mg to about 10 mg per unit dosage form. The determination of an appropriate dose for a given treatment is within the ordinary skill in the art. For additional details, one may refer to Remington, supra, Chapter 64.
  • polyethylene glycols are melted and micronized progesterone is dispersed into the molten polyethylene glycol carrier.
  • the micronized progesterone constitutes at least 30 % of the mixture.
  • a small amount of adjuvants such as titanium dioxide (as an opacifier) or pregelatinized starch (as a bulking agent) may be added to the mixture.
  • the melted mixture is cooled down through a lentilling machine to form flakes of lentils.
  • Lentils or even larger sized intermediate flakes can be prepared by melt granulation, lentilling and/or milling.
  • the lentils and the intermediate flakes are passed through a screen of appropriate sieve size to form smaller pieces of lentils.
  • These lentils are made into oral solid dosage forms such as tablets and caplets with techniques known to those skilled in the art, such as inj ection molding .
  • a mold is closed and clamped to prevent it from opening.
  • the formulation comprising the pharmaceutical and its carrier is injected into the cavities of the mold through a nozzle.
  • the amount of material that is injected into the mold is controlled by moving a screw to a predetermined distance inside the mold.
  • the screw may be displaced to facilitate packing of additional material into the mold cavities to fill the void generated when the mold cools after the first injection.
  • the various parameters of the injection and packing steps such as packing time, packing pressure, injection rate, and injection pressure can be adjusted.
  • the mold is cooled and the screw is returned to its pre-injection position.
  • the mold is opened and the molded parts (in this case, the solid unit dosage forms) are ejected. See Cuff and Raouf, supra.
  • the molded dosage form can be scored with conventional techniques. Alternatively, the mold can be set such that scoring is accomplished through the molding process. Other techniques known in the art may also be employed to prepare the solid dosage form, including, but not limited to, compression molding, tableting, and extrusion. See, for example, Remington, supra, Chapters 91-94.
  • a combination dosage form comprising progesterone and estrogen dosage forms can be prepared by first preparing the progesterone and estrogen formulations or dosage forms separately and then combining them.
  • progesterone and estrogen formulations can be compressed together to form one dosage form, for example, a multilayered tablet wherein each layer represents a progesterone or an estrogen formulation.
  • the progesterone dosage form and the estrogen dosage form can be encapsulated in one capsule.
  • one caplet of progesterone and one tablet of estradiol may be placed into a size # 1 hard shell gelatin capsule using an MG encapsulation machine fitted with custom built parts.
  • the estrogen formulation can be prepared by direct compression method.
  • the required quantities of estrogen and a portion of anhydrous lactose are mixed together in a blender.
  • the remaining anhydrous lactose, and, optionally, different types of color aluminum lake, are premixed by passing through a size 20 screen.
  • Other ingredients such as microcrystalline cellulose and polacriline potassium may be added to this mixture.
  • the granulation may be lubricated with magnesium stearate.
  • the granules are then made into tablets on a rotary tabletting machine fitted with appropriate punches and dies to achieve the desired tablet size, thickness, and hardness.
  • Estrogen may constitute from about 0.5 % to about 5 % by weight of the tablet, depending on the type of estrogen and the therapeutically effective estrogen blood levels needed for a given treatment.
  • estradiol constitutes about 1.29 % of the weight of the mixture so that a tablet containing 1 mg of estradiol weights about 80 mg and has a diameter of about 7/32 inch. The thickness of a tablet weighing 80 mg is about 0.107 inch.
  • the progesterone formulation is a caplet and the estrogen formulation is an estradiol tablet and the combination dosage form is a capsule.
  • one caplet of progesterone and one tablet of estradiol may be filled into a size #1 capsule using an MG encapsulation machine that is fitted with custom built parts.
  • the combination dosage form may be a capsule comprising a progesterone tablet and an estradiol powder.
  • progesterone formulation comprising a solid polymeric carrier.
  • preparation of a combination dosage form with a capsule of standard size 1 is now feasible.
  • a size 1 capsule has an internal diameter of about 0.253 inch and an internal length of about 0.748 inch when fully closed.
  • a progesterone caplet of up to a length of about 0.545 inch and an estradiol tablet of up to a thickness of about 0.115 inch can be placed end to end within a size 1 capsule.
  • the pharmaceutical dosage forms of this invention can be administered to patients needing hormonal therapy requiring progesterone, either as a replacement or as a supplement.
  • the effective amount of progesterone per dosage form can vary widely, in accordance with the needs of the patient, a dosage of from about 50 to about 500 milligrams per dosage form.
  • the method of administration generally involves swallowing, sucking, or chewing a dosage form of the present invention. Alternatively, the dosage form can be held in the mouth, under the tongue, or next to a cheek for sufficient period such that an effective amount of the progesterone is released from the dosage form. Additional methods of administering oral dosage forms are well known in the art.
  • the dosage forms of the present invention can be administered to treat or prevent a variety of conditions.
  • conditions include infertility related to non-receptive uterus, premenstrual tension, ovulation, primary dysmenorrhea and endometriosis, habitual abortion, respiratory depression in the Pickwickian syndrome, secondary amenorrhea, dysfunctional uterine bleeding, preeclampsia and toxemia of pregnancy, sexual infantilism, and post- menopausal symptoms.
  • infertility related to non-receptive uterus premenstrual tension, ovulation, primary dysmenorrhea and endometriosis, habitual abortion, respiratory depression in the Pickwickian syndrome, secondary amenorrhea, dysfunctional uterine bleeding, preeclampsia and toxemia of pregnancy, sexual infantilism, and post- menopausal symptoms.
  • infertility related to non-receptive uterus premenstrual tension, ovulation, primary dysmenor
  • Example 1 Progesterone Oral Caplets, 200 mg
  • composition for preparing progesterone oral caplets constituting 200 mg of progesterone per caplet is provided in Table 1 below.
  • the required quantities of polyethylene glycol 1450, polyethylene glycol 3350 and polyethylene glycol 8000 were melted into an appropriate size heated kettle.
  • the molten mixture was mixed for 5-10 minutes. Titanium dioxide was passed through a size 20 mesh into the molten mixture and the mixture was stirred for additional 10 minutes.
  • Micronized progesterone was dispersed into the kettle while mixing. After all the micronized progesterone has been added, the mixture was continuously stirred with the turbine speed on for approximately 50 minutes.
  • the material was transferred into a lentilling machine to form flakes or lentils.
  • the flakes or lentils were passed through a comminuting machine (Fitzpatrick) to provide smaller pieces of lentils.
  • caplets were molded using injection-molding technology. Methods of injection molding, the necessary equipment, and operating conditions are well known in the art. See, for example, U.S. Patents Nos. 4629621, 4744976, 4774074, 4806337, and 5082655, which are incorporated by reference.
  • the method was carried out using an all electric, 50-ton model ACT-50 injection molding machine.
  • the lentils were fed into the hopper of an injection molding machine (ACT 50-D Cincinnati Milacorn).
  • the caplets were prepared using 0.68" x 0.23" capsule shaped cold runner mold and cavity inserts.
  • the barrel temperamres were set to a temperature range of 130 -150 °F.
  • the shot size was set from 0.8 to 0.9 inch.
  • the mold chillers were set to a temperature of 8-10 °C.
  • the mold was then closed using semi-automatic mode and the selected mold cavities were filled with material flowing at 0.1 to 0.4 inch per second and at an injection pressure of 1000 to 1200 pounds per square inch.
  • the mold cooling time 10 to 14 seconds allowed the extruder to return to the starting shot size position of 0.8 to 0.9 inch.
  • the cooling timer timed out, allowing the mold to open 8 inches and the injection cycle pulses 2 to 4 times at a speed of 5 to 12 inches per second.
  • an air blast of 40 to 80 psi was directed at the spray to assure it was clear from the mold before starting the next cycle.
  • the automatic cycle mode could be activated. Cycle stability would be reached after running for approximately 5 minutes.
  • Example 2 Progesterone Oral Caplets, 200 mg
  • the composition for preparing progesterone oral caplets constituting 200 mg of progesterone per caplet is provided in Table 2 below.
  • Oral caplets constituting 200 mg of progesterone per caplet were prepared according to the process set forth in Example 1 except that during the injection molding process, mold cavities of 0.545" x 0.240" were used.
  • Example 3 Progesterone Oral Caplets. 200 mg The composition for preparing progesterone oral caplets constituting 200 mg of progesterone per caplet is provided in Table 3 below. TABLE 3
  • composition for preparing progesterone oral caplets constituting 150 mg of progesterone per caplet is provided in Table 4 below.
  • Example 5 Progesterone Oral Caplets. 150 mg
  • composition for preparing progesterone oral caplets constituting 150 mg of progesterone per caplet is provided in Table 5 below.
  • composition for preparing progesterone oral caplets constituting 75 mg of progesterone per caplet is provided in Table 6 below.
  • Example 6 The procedure for preparing 75 mg progesterone oral caplets was as set forth in Example 2 except that Example 6 has pregelatimzed starch as an additional ingredient.
  • Example 7 Progesterone Oral Caplets. 200 mg
  • composition for preparing progesterone oral caplets consti ting 200 mg of progesterone per caplet is provided in Table 7 below.
  • polyethylene glycol 1450, polyethylene glycol 3350 and polyethylene glycol 8000 were melted into an appropriate size heated kettle.
  • the molten carrier was mixed for 5-10 minutes. Titanium dioxide was added through a size 20 mesh into the molten mixture and the mixture was stirred for additional 10 minutes.
  • Micronized progesterone was dispersed into the kettle while mixing. After all the micronized progesterone has been added, stirring was continued for another 30 minutes.
  • the material was then poured onto a sheet of aluminum foil and allowed to cool and harden. The hard sheet was then passed through screen #20. The milled material was encapsulated using size 0 capsules.
  • Example 8 Progesterone Oral Caplets. 100 mg
  • composition for preparing progesterone oral caplets constituting 100 mg of progesterone per caplet is provided in Table 8 below.
  • micronized progesterone, lactose monohydrate, croscarmellose sodium, sodium lauryl sulfate and microcrystalline cellulose were transferred into an appropriate size mixer and mixed for 10 minutes.
  • Povidone was dissolved in ethyl alcohol while the powders were being mixed.
  • the powders were granulated with the povidone solution and the mixing continued until a moist granular mass was formed. Additional ethyl alcohol was added if needed to reach granulation and point.
  • the granulation was transferred to a tray dry oven and dried at 55 °C for 10-15 hrs or until loss on drying was not more than 2.0 %.
  • the dried granules were passed through a size 20 mesh screen together with colloidal silicon dioxide.
  • the milled granulation was lubricated by mixing with the required quantities of magnesium stearate in a suitable blender.
  • the granulate was then compressed to 190 mg per tablet on a rotary tableting machine using 1/4 inch flat faced beveled edge toolings.
  • 2 tablets of progesterone 100 mg were filled into each size 0 hard shell gelatin capsules.
  • composition for preparing an estradiol tablet constituting 1 mg estradiol per tablet is provided in Table 9 below.
  • Partial quantity of anhydrous lactose (e.g., about 17 %), the required quantities of D&C Red #30 (27 %) aluminum lake, FD&C Blue #1 (13 %) aluminum lake, D&C Yellow #10 (18 %) aluminum lake were passed through a size 20 mesh screen.
  • the required quantities of estradiol and the remaining quantities of anhydrous lactose were transferred into an appropriate size mixer and were mixed for 10 minutes.
  • the required quantities of microcrystalline cellulose, polacriline potassium and the milled colored mixtures were added into the lactose/estradiol .mixture and the composition was mixed for 10 minutes.
  • the granulate was then lubricated by mixing with the required quantities of magnesium stearate in the same mixer.
  • the granulate was then compressed to 80 mg per tablet using 7/32" round flat faced beveled edge tooling on a rotary tabletting machine.
  • the thickness range of the tablets was 0.104" to 0.112" and hardness range of the tablets is 2-6 K
  • Example 10 Bioavailability of Progesterone Caplet A pilot, single-dose, two period, randomized crossover study was conducted in healthy post-menopausal women to determine the relative oral bioavailability of two progesterone products under fasting conditions. The methodology for conducting randomized crossover studies are well-known in the medical and pharmaceutical arts.
  • Figure 1 shows the results of the experiment.
  • A represents the data for a capsule formulation of progesterone 200 mg of the present invention (hereinafter referred to as Watson progesterone) and “B” represents the data for commercially available formulation, Prometrium® 100 mg (x 2).
  • the formulation is the same as in Example 1 except that the lentils were passed through a size 20 mesh and encapsulated in size 0 capsules.
  • Figure 1 shows that the mean peak progesterone concentrations (Cmax) reached were 20.04 ⁇ 14.09 and 19.60 ⁇ 17.89 ng/ml following administration of the Watson progesterone . and Prometrium ® respectively.
  • the means were not found to be statistically different as assessed by ANOVA (analysis of variance).
  • the time to reach peak progesterone concentration (Tmax) was 2.31 + . 1.71 hrs for the Watson progesterone and 1.44 _+ 0.32 hrs for Prometrium®..
  • the means were not found to be statistically different at a p value of 0.05 or less.
  • Area under the curve (AUC) (0-t) following administration of the Watson progesterone and Prometrium® were not found to be statistically different as assessed by ANOVA (analysis of variance).
  • Example 11 Bioavailability of Progesterone Caplet when Administered with Estradiol
  • a pilot single dose, three period, randomized crossover study was conducted in 12 healthy postmenopausal women to determine the relative oral bioavailability of two progesterone products under fasted conditions.
  • the study involved administration of a single progesterone caplet (300 mg), a single estradiol tablet (1 mg) or a combination of the estradiol tablet and the progesterone caplet.
  • the progesterone caplet resulted in a Cmax of 75.78 ⁇ 5.3 ng/mL of plasma progesterone, with a Tmax of 2.62 + 1.5 hours and an AU o- 2 ) of 211.1 + 127 ng.hr /ml.
  • the normalized Cmax is 0.25 ng/mL and the normalized AUC is 0.7 ng.hr /ml/mg.
  • the normalized data was obtained by dividing the corresponding data with the dose.
  • the combination capsule resulted in a Cmax of 122.98 +/- 157.9 ng/mL of plasma progesterone with a Tmax of 1.88 +/- 0.98 hours and an AUQo-24) of 276.6 +/- 251.4 ng.hr /ml.
  • the normalized Cmax is 0.41 ng/mL and the normalized AUC(o-24) is 0.9 ng.hr /ml/mg.
  • the normalized Cmax of progesterone from the combination capsule (0.41 ng/ml) is about 60 % higher than the normalized Cmax for the progesterone-only caplet (0.25 ng/ml).
  • the normalized AUC for progesterone from the combination capsule (0.9 ng.hr/rru7mg) is about 30 % higher than the AUC for progesterone from the progesterone-only caplet (0.7 ng.hr /ml/mg).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une forme dosifiée orale apte à administrer un dosage combiné de progestérone, et qui après administration par le tube digestif permet d'obtenir une concentration de progestérone dans le sang comprise entre environ 0,1 ng/ml et environ 400 ng/ml. Ladite forme dosifiée possède une combinaison comprenant (a) une première forme solide qui comporte entre 25 mg et 500 mg de progestérone micronisée dans un excipient polyéthylèneglycol présentant un poids moléculaire moyen compris entre 1000 et 10000 et constituant au moins environ 30 % de ladite première forme solide; et (b) une seconde forme solide comprenant un oestrogène.
EP02707980A 2002-03-14 2002-03-14 Systeme d'administration de medicament oral a base de progesterone Withdrawn EP1482946A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/007562 WO2003077923A1 (fr) 2002-03-14 2002-03-14 Systeme d'administration de medicament oral a base de progesterone

Publications (1)

Publication Number Publication Date
EP1482946A1 true EP1482946A1 (fr) 2004-12-08

Family

ID=28038577

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02707980A Withdrawn EP1482946A1 (fr) 2002-03-14 2002-03-14 Systeme d'administration de medicament oral a base de progesterone

Country Status (6)

Country Link
EP (1) EP1482946A1 (fr)
JP (1) JP2005526083A (fr)
CN (1) CN1622810A (fr)
AU (1) AU2002242339A1 (fr)
CA (1) CA2479295A1 (fr)
WO (1) WO2003077923A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155361A1 (en) * 2005-08-18 2009-06-18 Masahiko Narasaki Tablet with multiple drug-containing sections
CN101541326A (zh) * 2006-11-29 2009-09-23 惠氏公司 雌激素/选择性雌激素受体调节剂（serm）和雌激素/孕酮双层药片
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2942568A1 (fr) * 2014-03-28 2015-10-01 Therapeuticsmd, Inc. Formulations de progesterone
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3174542A4 (fr) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Crème transdermique
ES3005883T3 (en) 2015-06-22 2025-03-17 Lipocine Inc 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
TWI661841B (zh) * 2017-04-19 2019-06-11 三凡生技研發股份有限公司 用於分散疏水性植物萃取物之載劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
US3828106A (en) * 1972-01-03 1974-08-06 Biolog Concepts Inc Novel oral pharmaceutical dosage form
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03077923A1 *

Also Published As

Publication number Publication date
JP2005526083A (ja) 2005-09-02
WO2003077923A1 (fr) 2003-09-25
AU2002242339A1 (en) 2003-09-29
CN1622810A (zh) 2005-06-01
CA2479295A1 (fr) 2003-09-25

Similar Documents

Publication Publication Date Title
US6544553B1 (en) Dosage forms and methods for oral delivery of progesterone
WO2003077923A1 (fr) Systeme d'administration de medicament oral a base de progesterone
US20090075961A1 (en) Testosterone Oral Dosage Formulations And Associated Methods
JP5911509B2 (ja) 被覆不正改変抵抗性制御放出剤形
KR102164693B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
CN101010068B (zh) 含有湿气敏感性药物的熔融颗粒的快速释放组合物及其制备方法
HRP20000434A2 (en) Celecoxib compositions
EP0991415B1 (fr) Forme posologique solide et orale, comprenant de la ribavirine pour administration par voie orale, et son procede de fabrication
KR101872561B1 (ko) 아로마타제 억제제를 포함하는 제약 조성물
JP2019108366A (ja) Ｃｇｒｐ活性化合物の錠剤製剤
AU748359B2 (en) Controlled-release formulations
WO2021107967A1 (fr) Compositions pharmaceutiques de lurasidone
US20260027058A1 (en) New modified release oral contraceptive composition
MXPA04011634A (es) Regimenes de tratamiento con bazedoxifeno.
JP2001511450A (ja) チアガビンを含有する制御放出性の医薬組成物
EP1049470B1 (fr) Formulations de tiagabine a liberation prolongee entrainant moins d'effets secondaires
US20250186337A1 (en) Chewable oral contraceptive
KR102210982B1 (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
WO2011069871A1 (fr) Méthode de contraception d'urgence à base d'acétate d'ulipristal
AU2002325404B2 (en) Extended Release Tiagabine Formulations with Reduced Side-effects
HK40108056A (zh) 纯孕激素口服避孕
EA051495B1 (ru) Фармацевтическая композиция, включающая мелатонин и дифенгидрамин или его фармацевтически приемлемую соль
CN113134007A (zh) 一种醋酸阿比特龙口服制剂及其制备方法
KR20050010843A (ko) 활성 성분을 지속 방출시키는, 옥스카바제핀 함유약제학적 조성물
MXPA00007471A (es) Composiciones de celecoxib

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040916

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/48 B

Ipc: 7A 61K 9/20 B

Ipc: 7A 61K 31/57 B

Ipc: 7A 61K 31/565 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060314